Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 471 All time
- Disclosed funding
- $19.1B 398 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AP Acta PharmaceuticalsCompany profile Develops investigational medicines for early intervention in Alzheimer’s disease. Develops investigational medicines for early intervention in Alzheimer’s disease. | $24M | Total seed financingSeed | Biotech | United States | Investors Undisclosed | |
| SB Silvia BioCompany profile Cell profiling and media additives for more predictable biopharmaceutical manufacturing. Cell profiling and media additives for more predictable biopharmaceutical manufacturing. | £3M | Seed | Biotech | United Kingdom | Investors | |
| H Enzyme-based catalysts for industrial chemical manufacturing. | $8M | Series A first closeSeries A | Biotech | United Kingdom | Investors | |
| s Quantitative biomarkers for diseases driven by protein aggregation. | €12M | Mixed financingUndisclosed | Biotech | Germany | Investors | |
| M MolagriCompany profile Molagri develops targeted crop-protection products for growers facing pesticide resistance. Molagri develops targeted crop-protection products for growers facing pesticide resistance. | Undisclosed | Seed | Biotech, Agritech | Canada | Investors | |
| O Climate-resilient cereal genetics for commercial seed programs. | €5M | Seed | Biotech, Agritech | Sweden | Investors | |
| B BoltzCompany profile Boltz builds biomolecular AI models and software for molecular design and drug-discovery research. Boltz builds biomolecular AI models and software for molecular design and drug-discovery research. | Undisclosed | Planned strategic investmentUndisclosed | Biotech | United States | Investors | |
| UB Undecimal BioCompany profile Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease. Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease. | $18M | Seed | Biotech | United Kingdom | Investors | |
| GB Giraffe Bio develops biochemical reagents for mineral recovery. | $6.4M | Seed | Biotech | Argentina | Investors | |
| ST Soufflé TherapeuticsCompany profile Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure. Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure. | $135M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.